Resources

The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons.

Australian Government response to the Senate Select Committee on Stillbirth Research and Education Report.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Pompe disease.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS II.

This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for paroxysmal nocturnal haemoglobinuria.

These guidelines assist approved aged care providers with police certificate and NDIS Worker Screening requirements.

The following spreadsheets provide quarterly 2019 data on childhood immunisation coverage by Primary Health Network (PHN) for all children and Aboriginal and Torres Strait Islander children.

This document outlines the structure, function, roles and responsibilities of the Australian Technical Advisory Group on Immunisation (ATAGI). The intended audience is ATAGI members and interested members of the general public.

This is the fifth annual operations report for ACFA. It covers the period 1 July 2016 to 30 June 2017.

This is the sixth annual operations report for ACFA. It covers the period 1 July 2017 to 30 June 2018.

This is the sixth annual report on funding and financing by the Aged Care Financing Authority (ACFA). It looks at the challenges facing the aged care sector in Australia and includes analysis of the data supplied by service providers in their 2016–17 financial reports.

This is the seventh annual report on funding and financing by the Aged Care Financing Authority (ACFA). It looks at the challenges facing the aged care sector in Australia and includes analysis of the data supplied by service providers in their 2017–18 financial reports.

This final report outlines the results of the Australasian Association of Clinical Biochemistry and Laboratory Medicine’s project to support genetics, eHealth and outreach.

This version of the manual was in effect from 1 July 2019 to 30 June 2021.

This document shows how we explain the different parts of the pricing schedule to older Australians and their families. As a home care provider, you will see these definitions when you enter your prices in the My Aged Care provider portal.

This report shows the monthly growth in ACFI subsidies compared to estimates for July 2019.

This framework focuses on identifying and understanding medical workforce issues that will benefit from national workforce planning.

This document contains the surveillance case definition for Q fever, which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This document contains the surveillance case definition for tularaemia, which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

Facilities registered to handle security sensitive biological agents (SSBAs) should use this form to report specific information about SSBAs.

Use this form to report the temporary handling and disposal of a known SSBA (previously confirmed in another facility) that you are not registered for. Temporary handlings must be for 7 working days or less.

Registered facilities must use this form when transferring security sensitive biological agents (SSBAs) to another facility within the same entity.

Use this form if you are already a registered facility and want to register a linked storage unit to store Tier 2 SSBAs under Part 4A.5 of the SSBA Standards. To register a new facility, use the Initial Registration form.

Use this form to report the transfer of security sensitive biological agents (SSBAs) into your facility. You must report as soon as possible and within 2 business days of the transfer occuring.

Facilities not registered to handle security sensitive biological agents (SSBAs) should use this form to report specific information about SSBAs.